<DOC>
	<DOC>NCT01494233</DOC>
	<brief_summary>The objective of this study is to evaluate the safety and efficacy of LX1033 over a range of dose levels in subjects with diarrhea-predominant Irritable Bowel Syndrome (IBS).</brief_summary>
	<brief_title>A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Male and female subjects, aged 18 to 70 years, with diarrheapredominant IBS (IBSD) with symptom onset at least 6 months prior to diagnosis Two or more days per week with at least one stool with a consistency of Type 6 or 7 (Bristol Stool Form Scale) Weekly average of worst abdominal pain in past 24 hours score of greater than or equal to 3.0 using a 010 point scale Ability to provide written, informed consent Inability to discontinue any current drug therapy for IBS, with the exception of bulking agents. Subjects will be allowed up to 2 doses of loperamide per week as rescue medication. Subjects who score severe abdominal pain (rated 7 or higher) 5 or more days per week Concomitant use of opioid analgesic drugs or drugs that affect bowel motility Any abnormalities or conditions deemed by the investigator as clinically significant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>